Compound class:
Synthetic organic
Comment: The structure for civorebrutinib was obtained from proposed INN list 129 (August 2023), where it is described as Bruton's tyrosine kinase inhibitor and antineoplastic agent. It is claimed in patent WO2019091440A1 (SINOMAB Bioscience) [1]. Review of SINOMAB's online pipeline page suggests that civorebrutinib is likely their lead BTK inhibitor SN1011.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
5-amino-3-[4-(5-chloropyridin-2-yl)oxyphenyl]-1-[(6R)-4-cyano-4-azaspiro[2.5]octan-6-yl]pyrazole-4-carboxamide |
Database Links ![]() |
|
CAS Registry No. | 2155853-43-1 (source: WHO INN record) |
GtoPdb PubChem SID | 485205989 |
PubChem CID | 132162130 |
Search Google for chemical match using the InChIKey | OSEITUBGGJDFBK-MRXNPFEDSA-N |
Search Google for chemicals with the same backbone | OSEITUBGGJDFBK |
UniChem Compound Search for chemical match using the InChIKey | OSEITUBGGJDFBK-MRXNPFEDSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | OSEITUBGGJDFBK-MRXNPFEDSA-N |